GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHA:600771)
China · Delayed Price · Currency is CNY 13.69
+0.19 (1.41%)
Sep 14, 2026, 3:00 PM CST
SHA:600771 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,413 | 1,368 | 1,220 | 1,283 | 1,116 | 849.3 |
Other Revenue | 1.76 | 1.52 | 1.21 | 1.34 | 14.53 | 4.93 |
| 1,414 | 1,369 | 1,221 | 1,284 | 1,131 | 854.22 | |
Revenue Growth | 5.46% | 12.11% | -4.88% | 13.56% | 32.37% | -23.00% |
Cost of Revenue | 475.73 | 450.09 | 329.93 | 350.72 | 404.77 | 333.11 |
Gross Profit | 938.63 | 919.21 | 891.49 | 933.3 | 725.95 | 521.11 |
Selling, General & Admin | 747.08 | 728.8 | 665.54 | 736.08 | 881.9 | 867.33 |
Research & Development | 38.99 | 38.47 | 38.59 | 31.38 | 28.96 | 25.19 |
Other Operating Expenses | 43.08 | 29.65 | 26.61 | 27.9 | 19.57 | 17.46 |
Operating Expenses | 829.26 | 796.82 | 800.75 | 820.11 | 952.63 | 883.95 |
Operating Income | 109.37 | 122.39 | 90.74 | 113.18 | -226.68 | -362.84 |
Interest Expense | -1.91 | -2.52 | -6.43 | -16.94 | -20.95 | -19.09 |
Interest & Investment Income | 1.11 | 1.16 | 1.77 | 2.97 | 0.97 | 4.94 |
Earnings From Equity Investments | - | - | - | - | -0.92 | - |
Other Non Operating Income (Expenses) | 3.17 | -0.34 | -0.11 | -0.41 | -6.89 | -10.5 |
EBT Excluding Unusual Items | 111.75 | 120.7 | 85.97 | 98.81 | -254.48 | -387.48 |
Gain (Loss) on Sale of Investments | -2.68 | -2.26 | -7.73 | - | - | -4.22 |
Gain (Loss) on Sale of Assets | - | - | -0.02 | 0.19 | -0.02 | 0.37 |
Asset Writedown | -19.07 | -18.91 | -4.71 | -0.02 | -19.89 | - |
Other Unusual Items | 20.03 | 3.51 | 7.33 | 1.39 | 9.25 | 38.7 |
Pretax Income | 110.02 | 103.04 | 80.85 | 100.37 | -265.13 | -352.63 |
Income Tax Expense | 37.37 | 39.35 | -2.75 | 7.52 | -2.13 | -20.2 |
Earnings From Continuing Operations | 72.66 | 63.69 | 83.6 | 92.85 | -263.01 | -332.43 |
Minority Interest in Earnings | -1.81 | -0.65 | -9.15 | -2.77 | 12.98 | 16.19 |
Net Income | 70.84 | 63.04 | 74.45 | 90.08 | -250.02 | -316.24 |
Net Income to Common | 70.84 | 63.04 | 74.45 | 90.08 | -250.02 | -316.24 |
Net Income Growth | -22.75% | -15.32% | -17.35% | - | - | - |
Shares Outstanding (Basic) | 494 | 485 | 496 | 500 | 490 | 494 |
Shares Outstanding (Diluted) | 494 | 485 | 573 | 500 | 490 | 494 |
Shares Change | -12.54% | -15.32% | 14.44% | 2.08% | -0.79% | 8.08% |
EPS (Basic) | 0.14 | 0.13 | 0.15 | 0.18 | -0.51 | -0.64 |
EPS (Diluted) | 0.14 | 0.13 | 0.13 | 0.18 | -0.51 | -0.64 |
EPS Growth | -11.68% | 0% | -27.78% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 227.88 | 191.65 | 103.61 | 212.99 | 244.76 | 63.17 |
Free Cash Flow Per Share | 0.46 | 0.40 | 0.18 | 0.43 | 0.50 | 0.13 |
Gross Margin | 66.36% | 67.13% | 72.99% | 72.69% | 64.20% | 61.00% |
Operating Margin | 7.73% | 8.94% | 7.43% | 8.82% | -20.05% | -42.48% |
Profit Margin | 5.01% | 4.60% | 6.10% | 7.02% | -22.11% | -37.02% |
Free Cash Flow Margin | 16.11% | 14.00% | 8.48% | 16.59% | 21.65% | 7.40% |
EBITDA | 142.95 | 158.07 | 135.88 | 152.46 | -187.97 | -324.45 |
EBITDA Margin | 10.11% | 11.54% | 11.13% | 11.87% | -16.62% | -37.98% |
D&A For EBITDA | 33.58 | 35.68 | 45.14 | 39.27 | 38.71 | 38.39 |
EBIT | 109.37 | 122.39 | 90.74 | 113.18 | -226.68 | -362.84 |
EBIT Margin | 7.73% | 8.94% | 7.43% | 8.82% | -20.05% | -42.48% |
Effective Tax Rate | 33.96% | 38.19% | - | 7.50% | - | - |
Revenue as Reported | 1,414 | 1,369 | 1,221 | 1,284 | 1,131 | 854.22 |
Advertising Expenses | - | 27.87 | 19.4 | 17.23 | 14.98 | 90.22 |